In a significant development for the oncology community, new data from the phase III MonumenTAL-3 trial has revealed that combinations of the bispecific T-cell engager talquetamab (Talvey) significantly outperform standard-of-care regimens for patients with relapsed or refractory multiple myeloma (RRMM). The findings, which were unveiled at the European Hematology Association (EHA) annual congress in Stockholm and simultaneously published in the New England Journal of Medicine, suggest a potential paradigm shift in how early-line relapsed myeloma is managed.
Main Facts: A Shift in Treatment Strategy
The MonumenTAL-3 trial investigated two distinct combinations involving talquetamab: talquetamab plus daratumumab and pomalidomide (Tal-DP), and talquetamab plus daratumumab (Tal-D). Researchers compared these to a control arm consisting of daratumumab, pomalidomide, and dexamethasone.
The study demonstrated that both talquetamab-based regimens provided profound improvements in progression-free survival (PFS) and overall survival (OS). Specifically, patients treated with the triple-drug regimen (Tal-DP) experienced a 72% reduction in the risk of disease progression or death, while those on the doublet regimen (Tal-D) saw a 67% reduction compared to the control arm. These statistics underscore the potency of targeting GPRC5D—a protein highly expressed on myeloma cells—in tandem with the immune-modulating power of daratumumab and pomalidomide.
Chronology of the Clinical Development
The journey of talquetamab from a promising molecule to a clinical standard has been rapid.
- 2023: Talquetamab received accelerated approval from the U.S. Food and Drug Administration (FDA) for patients with RRMM who had already exhausted four or more lines of prior therapy. This was a landmark moment for patients with limited options, as it introduced a novel mechanism of action—bispecific T-cell redirection targeting GPRC5D and CD3.
- Late 2022 – Early 2025: The MonumenTAL-3 trial was conducted across 182 international sites, enrolling 864 patients. The trial was designed to evaluate whether moving talquetamab earlier into the treatment sequence (after one or more lines of therapy) could provide better outcomes than existing standard protocols.
- The MonumenTAL-2 Milestone: During this same window, the MonumenTAL-2 study provided early evidence that combining talquetamab with pomalidomide could elicit deep and durable responses in patients who had received as few as two previous lines of therapy.
- June 2025 (EHA Congress): The formal presentation of the MonumenTAL-3 data solidified the clinical validity of these combinations, providing the long-term survival data necessary to push these regimens into wider clinical practice.
Supporting Data: Survival and Efficacy Metrics
The primary endpoints of the MonumenTAL-3 trial provide compelling evidence for the efficacy of these combinations. Among patients who had previously received at least one line of therapy, the 24-month progression-free survival (PFS) rates were striking:
- Tal-DP Arm: 81.3%
- Tal-D Arm: 77.6%
- Control Arm (Daratumumab + Pomalidomide + Dexamethasone): 51.2%
The overall survival (OS) benefit was equally pronounced. At the 24-month mark, 89.2% of patients in the Tal-DP group and 87.9% in the Tal-D group were alive, compared to 79.1% in the control group. The hazard ratios (HR) for progression—0.28 for the triple combination and 0.33 for the doublet—represent some of the most significant improvements seen in recent years for this patient population.
Safety and Tolerability Profiles
As with any potent immunotherapy, the trial highlighted a rigorous safety profile. The most prevalent grade ≥3 adverse event was neutropenia, which occurred in 76.4% of the Tal-DP group and 86.2% of the control group. Researchers attributed the higher rates of hematologic toxicity in the triple-drug arm to the additive myelosuppressive effects of pomalidomide.
Serious adverse events, including pneumonia, were observed across all arms. However, the study authors noted that the safety profile was generally consistent with the known toxicities of the individual agents, suggesting that clinicians can manage these risks through established monitoring protocols.
Official Responses and Clinical Perspectives
Dr. Peter M. Voorhees of the Wake Forest University School of Medicine, the lead investigator of the trial, emphasized that these combinations offer a flexible and effective "early-line" strategy.
"The addition of pomalidomide to talquetamab plus daratumumab therapy appeared to be associated with increases in progression-free survival, duration of response, and overall survival," Dr. Voorhees noted in the study publication. However, he cautioned that this benefit must be weighed against the increased risk of severe infections and hematologic toxicity.
The research team highlighted that the synergy between these drugs is not accidental. Daratumumab modulates the immune microenvironment—specifically by reducing immunosuppressive regulatory T cells and enhancing the activity of cytotoxic T cells. This "priming" of the immune system allows talquetamab to more effectively bridge T cells to myeloma cells, facilitating a more potent eradication of the cancer.
Implications for Future Myeloma Care
The implications of the MonumenTAL-3 results are profound for the field of hematology-oncology.
1. Earlier Intervention
By moving talquetamab into earlier lines of therapy (specifically after the first line), oncologists can hit the cancer harder before it develops further resistance mechanisms. The data suggests that waiting until the fourth or fifth line of treatment—the initial context of talquetamab’s approval—may be losing out on the window of maximum therapeutic benefit.
2. Personalized Treatment Selection
The trial results do not suggest a "one-size-fits-all" approach. While the Tal-DP (triple) combination showed slightly superior survival metrics, it also came with a higher burden of toxicity. The study provides clinicians with a clear framework for decision-making: patients with robust physiological reserves might benefit from the triple combination, while those at higher risk for complications might find the Tal-D (doublet) combination a safer, yet still highly effective, alternative.
3. Broadening the Therapeutic Arsenal
With the success of MonumenTAL-3, the therapeutic landscape for RRMM is expanding. The success of GPRC5D-targeted therapy confirms that B-cell maturation antigen (BCMA) is not the only viable target for immunotherapy in myeloma. This provides a critical fallback for patients whose disease may have become resistant to BCMA-directed therapies, such as CAR-T cells or other bispecific antibodies.
4. Global Accessibility
Enrolling 864 patients across 18 countries ensures that the findings are robust and generalizable across different demographic and clinical backgrounds. With a median age of 64 and a diverse participant pool, the data provides strong evidence that these regimens can be implemented in standard clinical settings worldwide, provided that centers have the capability to manage the specific adverse events associated with T-cell engaging therapies.
Conclusion
The MonumenTAL-3 trial represents a milestone in the treatment of relapsed or refractory multiple myeloma. By demonstrating that talquetamab-based regimens can significantly extend both the duration of disease control and the survival of patients, the trial provides a new gold standard for early-line relapsed therapy. As medical centers begin to integrate these findings into their standard practices, the focus will now shift to long-term monitoring and optimizing supportive care strategies to mitigate the side effects of these potent combinations. For patients, this translates into a higher probability of achieving deep, durable remissions, potentially changing the trajectory of a disease that has historically been defined by rapid recurrence.
